On 6 December 2024, Novo Holdings A/S, Novo Nordisk’s holding company, announced that the European Commission approved its acquisition of the US global contract development and manufacturing organisation, Catalent, Inc.
The acquisition is expected to be completed towards the end of 2024, subject to customary closing conditions, including regulatory approvals in other jurisdictions.
In connection with the transaction, Novo Nordisk will also acquire three manufacturing (fill finish) sites from Novo Holdings in Italy, Belgium and the US. According to Novo Nordisk, the acquisition of the filling sites will expand its manufacturing capacity for its diabetes and obesity drugs, while providing future optionality and flexibility for its existing supply network.